Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA)

Prostate Cancer and Prostatic Diseases volume 7, pages 132–137 (2004)Cite this article

Abstract

Recent studies have reported enhanced prostate cancer detection in Caucasians with serum human glandular kallikrein 2 (hK2) in combination with total- (tPSA) and free-prostate-specific antigen (fPSA). The purpose of this study is to validate these findings in an African-American patient cohort. A total of 137 African-American men were found by routine screening to have tPSA levels above 2.5 ng/ml or an abnormal digital rectal examination. Sera were drawn prior to biopsy of the prostate and Hybritech® PSA, FPSA and hK2 (for research use only, not for use in diagnostic procedures) concentrations were determined on Beckman Coulter's Access® immunoanalyzer. These independent variables and the ratios of percent fPSA (%fPSA), hK2/tPSA, hK2/fPSA, and hK2*tPSA/fPSA were compared between cancer and non-cancer groups. In all, 49 of 137 men had prostate cancer. hK2 and its calculated ratios outperformed tPSA on receiver operator characteristic (ROC) analysis, but %fPSA had statistically the highest area under the curve (AUC) at 0.801. When restricting the analysis to only the tPSA range of 4.0–10 ng/ml, hK2/fPSA yielded the highest AUC (0.721). The ratio of hK2/fPSA was also found to increase the positive predictive value (PPV) of the %fPSA ranges less than 10 and 10–25%. %fPSA offered the best performance and highest specificity in prostate cancer detection in African-American males over the entire range of tPSA. hK2/fPSA may offer modest improvement in the tPSA range of 4.0–10 ng/ml. Furthermore, hK2/fPSA can enhance the PPV of low %fPSA values. Therefore, the use of multiple biomarkers may ultimately increase the specificity of prostate cancer screening in African-American men.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Paquette EL et al. Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era. Cancer 2001; 92: 2673–2679.

    Article  CAS  Google Scholar 

  2. Bartsch G et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417–424.

    Article  CAS  Google Scholar 

  3. Kubota Y, Ito K, Imai K, Yamanak H . Effectiveness of mass screening for the prognosis of prostate cancer patients in japanese communities. Prostate 2002; 50: 262–269.

    Article  Google Scholar 

  4. Catalona WJ, Smith DS, Ornstein DK . Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452–1455.

    Article  CAS  Google Scholar 

  5. Smith DS et al. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 1998; 160: 1734–1738.

    Article  CAS  Google Scholar 

  6. Okihara K et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 2002; 167: 2017–2024.

    Article  Google Scholar 

  7. Tanguay S et al. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002; 59: 261–265.

    Article  CAS  Google Scholar 

  8. Brawer MK, Cheli CD, Neaman IE . Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163: 1476–1480.

    Article  CAS  Google Scholar 

  9. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW . Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998; 35: 275–368.

    Article  CAS  Google Scholar 

  10. Charlesworth MC et al. Detection of a prostate-specific protein, human glandular kallikrein (hK2) in sera of patients with elevated prostate-specific antigen levels. Urology 1997; 49: 487–493.

    Article  CAS  Google Scholar 

  11. Kwiatkowski MK et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic ‘gray zone’ of total PSA 4 to 10 ng/Ml. Urology 1998; 52: 360–365.

    Article  CAS  Google Scholar 

  12. Partin AW et al. Use of Human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 1999; 54: 839–845.

    Article  CAS  Google Scholar 

  13. Becker C et al. Discrimination of men with prostate cancer from those with benign disease by measurement of human glandular kallikrein 2 (hK2) in serum. J Urology 2000; 163: 311–316.

    Article  CAS  Google Scholar 

  14. Becker C et al. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/ml or greater. Urology 2000; 55: 694–699.

    Article  CAS  Google Scholar 

  15. Nam RK et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 2000; 18: 1036–1042.

    Article  CAS  Google Scholar 

  16. Catalona WJ, Antenor JV, Roehl KA . Screening for prostate cancer in high risk populations. J Urol 2002; 168: 1980–1984.

    Article  Google Scholar 

  17. Brawley OW, Knopf K, Merrill R . The epidemiology of prostate cancer part I: descriptive epidemiology. Semin Urol Oncol 1998; 16: 187–192.

    PubMed  CAS  Google Scholar 

  18. Miller BA et al. Cancer statistics review: 1973–1989. National Cancer Institute:Bethesda, MD 1992.

    Google Scholar 

  19. Gargiullo P et al. Recent trends in mortality rates for four major cancers, by sex and race—United States, 1990–1998. MMWR 2002; 51: 49–53.

    Google Scholar 

  20. Magklara A et al. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 1999; 45: 1960–1966.

    PubMed  CAS  Google Scholar 

  21. Riegman PH et al. Characterization of the human kallikrein locus. Genomics 1992; 14: 6–11.

    Article  CAS  Google Scholar 

  22. Yousef GM, Eleftherios PD . The new human tissue kallikrein gene family: structure, function, and association to disease. Endocrine Rev 2001; 22: 184–204.

    CAS  Google Scholar 

  23. Darson MF et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999; 53: 939–944.

    Article  CAS  Google Scholar 

  24. Herraha AM et al. Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. Cancer 2001; 92: 2975–2984.

    Article  Google Scholar 

  25. Stamey TA et al. Molecular genetic profiling of gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 2001; 166: 2171–2177.

    Article  CAS  Google Scholar 

  26. Magklara A et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 2000; 56: 527–532.

    Article  CAS  Google Scholar 

  27. Scorilas A et al. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate 2003; 54: 220–229.

    Article  CAS  Google Scholar 

  28. Recker F et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ confined prostate cancer compared with prostate-specific antigen. Urology 2000; 55: 481–485.

    Article  CAS  Google Scholar 

  29. Haese A et al. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 2003; 54: 181–186.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Louisiana State University Health Sciences Center, New Orleans, LA, USA

    B J Martin, K Sterling, M Ward, D Lifsey, D Mercante, L Martin & W Rayford

  2. Hybritech Incorporated, a Subsidiary of Beckman Coulter, Inc., San Diego, CA, USA

    J A Finlay & J M Jainto

Authors
  1. B J Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J A Finlay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Sterling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Ward
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Lifsey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Mercante
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J M Jainto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W Rayford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W Rayford.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, B., Finlay, J., Sterling, K. et al. Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA). Prostate Cancer Prostatic Dis 7, 132–137 (2004). https://doi.org/10.1038/sj.pcan.4500706

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500706

Keywords

This article is cited by

Search

Advanced search

Quick links